The Landscape of Targeted Therapies in TNBC

The Landscape of Targeted Therapies in TNBC

Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes for TNBC unfortunately remain poor. The median overall survival for patients with metastatic TNBC is approximately eighteen...

Full description

Bibliographic Details
Main Authors:	Elena Vagia, Devalingam Mahalingam, Massimo Cristofanilli
Format:	Article
Language:	English
Published:	MDPI AG 2020-04-01
Series:	Cancers
Subjects:	triple negative breast cancer molecular profiling DNA damage repair targeted treatment personalized medicine
Online Access:	https://www.mdpi.com/2072-6694/12/4/916

Similar Items

Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology
by: Aiswarya Chaudhuri, et al.
Published: (2023-05-01)

The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification
by: Lijuan Weng, et al.
Published: (2024-03-01)

TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy
by: Desh Deepak Singh, et al.
Published: (2021-07-01)

Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches
by: Paola Pastena, et al.
Published: (2024-02-01)

Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
by: Aiswarya Chaudhuri, et al.
Published: (2022-04-01)

Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
by: Jieun Lee
Published: (2023-02-01)

LC–MS Based Lipidomics Depict Phosphatidylethanolamine as Biomarkers of TNBC MDA-MB-231 over nTNBC MCF-7 Cells
by: Alan Rubén Estrada-Pérez, et al.
Published: (2022-10-01)

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
by: Desh Deepak Singh, et al.
Published: (2021-10-01)

The Potential of PSMA as a Vascular Target in TNBC
by: Amelie Heesch, et al.
Published: (2023-02-01)

Clinically Translatable Approaches of Inhibiting TGF-β to Target Cancer Stem Cells in TNBC
by: Andrew Sulaiman, et al.
Published: (2021-10-01)

Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC
by: Paola Ferrari, et al.
Published: (2022-01-01)

Recent advances in targeted strategies for triple-negative breast cancer
by: Shuangli Zhu, et al.
Published: (2023-08-01)

Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
by: Won-Ji Ryu, et al.
Published: (2021-09-01)

Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq
by: Radhakrishnan Vishnubalaji, et al.
Published: (2021-12-01)

The Differential Metabolic Signature of Breast Cancer Cellular Response to Olaparib Treatment
by: Domenica Berardi, et al.
Published: (2022-07-01)

Salvia chinensis Benth Inhibits Triple-Negative Breast Cancer Progression by Inducing the DNA Damage Pathway
by: Kai-nan Wang, et al.
Published: (2022-08-01)

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
by: Jin Sun Lee, et al.
Published: (2020-05-01)

New RAD51 Inhibitors to Target Homologous Recombination in Human Cells
by: Irina S. Shkundina, et al.
Published: (2021-06-01)

Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance
by: Dong Won Baek, et al.
Published: (2020-07-01)

Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?
by: Emma E. Newton, et al.
Published: (2022-01-01)

Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer—A Review of Molecular Characterisation, Therapeutic Targets and Future Trends
by: Karen Pinilla, et al.
Published: (2022-08-01)

Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer
by: Eva Kudelova, et al.
Published: (2022-11-01)

Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro
by: Hoon Sik Choi, et al.
Published: (2021-08-01)

Overcoming Therapy Resistance and Relapse in TNBC: Emerging Technologies to Target Breast Cancer-Associated Fibroblasts
by: Farhana Mollah, et al.
Published: (2021-12-01)

Bromodomain Protein BRD4-Mediated Mutant p53 Transcription Promotes TNBC Progression
by: Julie Xia Zhou, et al.
Published: (2022-12-01)

Genetic Counseling in the Follow-up of Breast Cancer patients; Conversion of a Luminal Tumor to TNBC
by: Hamid Ahmadi, et al.
Published: (2020-02-01)

Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors
by: Junjun Li, et al.
Published: (2022-04-01)

Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells
by: Andrew Sulaiman, et al.
Published: (2020-08-01)

Synthetic Lethality Targeting Polθ
by: Małgorzata Drzewiecka, et al.
Published: (2022-06-01)

Knockdown of CAVEOLIN-1 Sensitizes Human Basal-Like Triple-Negative Breast Cancer Cells to Radiation
by: Man Zou, et al.
Published: (2017-11-01)

1-Chromonyl-5-Imidazolylpentadienone Demonstrates Anti-Cancer Action against TNBC and Exhibits Synergism with Paclitaxel
by: Karan Modi, et al.
Published: (2020-08-01)

Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC)
by: Nicoletta Cordani, et al.
Published: (2023-03-01)

Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse
by: Mohammed Ridha Moamin, et al.
Published: (2023-11-01)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
by: Fleisher B, et al.
Published: (2016-10-01)

Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target
by: Malvina Koni, et al.
Published: (2022-08-01)

NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers
by: François Bertucci, et al.
Published: (2020-03-01)

GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC
by: Nesrine Mabrouk, et al.
Published: (2023-06-01)

BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells
by: Teresa Rossi, et al.
Published: (2023-01-01)

Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
by: Fokhrul Hossain, et al.
Published: (2021-07-01)

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer
by: Todd M. Pitts, et al.
Published: (2020-03-01)